Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NexMed, a developer of innovative transdermal products, has said that Health Canada has accepted the new drug submission or NDS for its topical erectile dysfunction treatment for review.
Subscribe to our email newsletter
The company said that Health Canada’s target is to complete review within 300 days for 90% of submissions.
Vivian Liu, president and CEO of NexMed, said: “We are very pleased to reach another regulatory milestone. The acceptance of the NDS for review is a positive development for the discussions with potential commercialization partners in Canada.”